Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1‐CXCR2 axis
Cancer Science · 2023-09 · 114 (9) · 3666-3678
DOI: 10.1111/cas.15901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 12.07.2023. Verfasst von Masataka Hayashi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline Japan, Japan Society for the Promotion of Science, Pancreas Research Foundation of Japan.
Abstract (Originalsprache)
Intratumor bacteria modify the tumor immune microenvironment and influence outcomes of various tumors. Periodontal pathogen Fusobacterium nucleatum has been detected in pancreatic cancer tissues and is associated with poor prognosis. However, it remains unclear how F. nucleatum affects pancreatic cancer. Here, we compared clinical features with F. nucleatum colonization in pancreatic cancer tissues. F. nucleatum was detected in 15.5% (13/84) of pancreatic cancer patients. The tumor size was significantly larger in the F. nucleatum ‐positive group than in the negative group. To clarify the biological effect of intratumor F. nucleatum on pancreatic cancer progression, we performed migration/invasion assays and cytokine array analysis of cancer cells cocultured with F. nucleatum . F. nucleatum promoted CXCL1 secretion from pancreatic cancer cells, leading to cancer progression through autocrine signaling. Intratumor F. nucleatum suppressed tumor‐infiltrating CD8 + T cells by recruiting myeloid‐derived suppressor cells (MDSCs) to the tumor in an F. nucleatum ‐injected subcutaneous pancreatic cancer mouse model, resulting in tumor progression. Furthermore, tumor growth accelerated by F. nucleatum was suppressed by MDSC depletion or cytokine inhibitors. Intratumor F. nucleatum promoted pancreatic cancer progression through autocrine and paracrine mechanisms of the CXCL1‐CXCR2 axis. Blockade of the CXCL1‐CXCR2 axis may be a novel therapeutic approach for patients with intratumor F. nucleatum ‐positive pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Bachelor of Health Science, Kyushu University, Fukuoka, Japan.
- Department of Anatomical Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Naoki Ikenaga, Yoshinao Oda
Förderung
- GlaxoSmithKline Japan
- Japan Society for the Promotion of Science
- Pancreas Research Foundation of Japan
- Shinnihon Foundation of Advanced Medical Treatment Research
Zitieren
APA
Hayashi, M., Ikenaga, N., Nakata, K., Luo, H., Zhong, P., Date, S., Oyama, K., Higashijima, N., Kubo, A., Iwamoto, C., Torata, N., Abe, T., Yamada, Y., Ohuchida, K., Oda, Y., & Nakamura, M. (2023). Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1‐CXCR2 axis. Cancer Science, 114(9), 3666-3678. https://doi.org/10.1111/cas.15901
Vancouver
Hayashi M, Ikenaga N, Nakata K, Luo H, Zhong P, Date S, et al. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1‐CXCR2 axis. Cancer Science. 2023;114(9):3666-3678. doi:10.1111/cas.15901
BibTeX
@article{Hayashi2023,
author = {Hayashi, Masataka and Ikenaga, Naoki and Nakata, Kohei and Luo, Haizhen and Zhong, PingShan and Date, Satomi and Oyama, Koki and Higashijima, Nobuhiro and Kubo, Akihiro and Iwamoto, Chika and Torata, Nobuhiro and Abe, Toshiya and Yamada, Yutaka and Ohuchida, Kenoki and Oda, Yoshinao and Nakamura, Masafumi},
title = {Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1‐CXCR2 axis},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {9},
pages = {3666--3678},
doi = {10.1111/cas.15901}
}
EUVIMED